Common Contracts
37 similar Underwriting Agreement contracts by Gamida Cell Ltd., American Superconductor Corp /De/, Anaptysbio Inc, others
JASPER THERAPEUTICS, INC. 60,000,000 Shares of Common Stock, par value $0.0001 per share UNDERWRITING AGREEMENTUnderwriting Agreement • January 25th, 2023 • Jasper Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Jasper Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell an aggregate of 60,000,000 shares (the “Firm Shares”) of the Company’s voting common stock, $0.0001 par value per share (the “Common Stock”), to the several underwriters (collectively, the “Underwriters”) named in Schedule I to this agreement (this “Agreement”), for whom Credit Suisse Securities (USA) LLC, William Blair & Company, L.L.C. and Oppenheimer & Co. Inc. are acting as representatives (the “Representatives”). The Company has also agreed to grant to the Underwriters an option (the “Option”) to purchase up to an additional 9,000,000 shares of Common Stock (the “Option Shares”) on the terms set forth in Section 1(b) hereof. The Firm Shares and the Option Shares are hereinafter collectively referred to as the “Shares.”
ORDINARY SHARES, NOMINAL VALUE NIS 0.01 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • September 30th, 2022 • Gamida Cell Ltd. • Biological products, (no disgnostic substances) • New York
Gamida Cell Ltd., a limited liability company organized under the laws of the State of Israel (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell an aggregate of 12,905,000 shares (the “Firm Shares”) of the Company’s ordinary shares with a nominal value of New Israeli Shekel (“NIS”) 0.01 per share (the “Ordinary Shares”), to the several underwriters (collectively, the “Underwriters”) named in Schedule I to this agreement (this “Agreement”), for whom Piper Sandler & Co. is acting as a representative (the “Representative”). The Company has also agreed to grant to the Underwriters an option (the “Option”) to purchase up to an additional 1,935,750 ordinary shares of the Company (the “Option Shares”) on the terms set forth in Section 1(b) hereof. The Firm Shares and the Option Shares are hereinafter collectively referred to as the “Shares.”
ORDINARY SHARES, NOMINAL VALUE NIS 0.01 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • December 21st, 2020 • Gamida Cell Ltd. • Biological products, (no disgnostic substances) • New York
Gamida Cell Ltd., a limited liability company organized under the laws of the State of Israel (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell an aggregate of 8,125,000 shares (the “Firm Shares”) of the Company’s ordinary shares with a nominal value of New Israeli Shekel (“NIS”) 0.01 per share (the “Ordinary Shares”), to the several underwriters (collectively, the “Underwriters”) named in Schedule I to this agreement (this “Agreement”), for whom Piper Sandler & Co. and Evercore Group L.L.C. are acting as representatives (the “Representatives”). The Company has also agreed to grant to the Underwriters an option (the “Option”) to purchase up to an additional 1,218,750 ordinary shares of the Company (the “Option Shares”) on the terms set forth in Section 1(b) hereof. The Firm Shares and the Option Shares are hereinafter collectively referred to as the “Shares.”
3,670,000 Shares of Common Stock AMERICAN SUPERCONDUCTOR CORPORATION UNDERWRITING AGREEMENTUnderwriting Agreement • October 26th, 2020 • American Superconductor Corp /De/ • Motors & generators • New York
ORDINARY SHARES, NOMINAL VALUE NIS 0.01 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • May 20th, 2020 • Gamida Cell Ltd. • Biological products, (no disgnostic substances) • New York
Gamida Cell Ltd., a limited liability company organized under the laws of the State of Israel (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell an aggregate of 13,333,334 shares (the “Firm Shares”) of the Company’s ordinary shares with a nominal value of New Israeli Shekel (“NIS”) 0.01 per share (the “Ordinary Shares”), to the several underwriters (collectively, the “Underwriters”) named in Schedule I to this agreement (this “Agreement”), for whom Piper Sandler & Co. and Evercore Group L.L.C. are acting as representatives (the “Representatives”). The Company has also agreed to grant to the Underwriters an option (the “Option”) to purchase up to an additional 2,000,000 ordinary shares of the Company (the “Option Shares”) on the terms set forth in Section 1(b) hereof. The Firm Shares and the Option Shares are hereinafter collectively referred to as the “Shares.”
●] Shares SITIME CORPORATION Common Stock ($0.0001 Par Value Per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • October 23rd, 2019 • SITIME Corp • Semiconductors & related devices • New York
SiTime Corporation, a Delaware corporation (the “Company”), proposes to sell to the several underwriters (the “Underwriters”) named on Schedule I hereto for whom you are acting as representatives (the “Representatives”), an aggregate of [●] shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”). The respective amounts of the Firm Shares to be so purchased by the several Underwriters are set forth opposite their names on Schedule I hereto. The Company is a subsidiary of MegaChips Corporation (“MegaChips”), a corporation organized under the laws of Japan. The Company also proposes to sell at the Underwriters’ option an aggregate of up to [●] additional shares of the Company’s Common Stock (the “Option Shares”) as set forth below.
●] SHARES ORDINARY SHARES, NOMINAL VALUE NIS 0.01 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • June 24th, 2019 • Gamida Cell Ltd. • Biological products, (no disgnostic substances) • New York
Gamida Cell Ltd., a limited liability company organized under the laws of the State of Israel (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell an aggregate of [●] shares (the “Firm Shares”) of the Company’s ordinary shares with a nominal value of New Israeli Shekel (“NIS”) 0.01 per share (the “Ordinary Shares”), to the several underwriters (collectively, the “Underwriters”) named in Schedule I to this agreement (this “Agreement”), for whom RBC Capital Markets, LLC and JMP Securities LLC are acting as representatives (the “Representatives”). The Company has also agreed to grant to the Underwriters an option (the “Option”) to purchase up to an additional [●] ordinary shares of the Company (the “Option Shares”) on the terms set forth in Section 1(b) hereof. The Firm Shares and the Option Shares are hereinafter collectively referred to as the “Shares.”
●] SHARES ORDINARY SHARES, NOMINAL VALUE NIS 0.01 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • October 17th, 2018 • Gamida Cell Ltd. • Biological products, (no disgnostic substances) • New York
Gamida Cell Ltd., a limited liability company organized under the laws of the State of Israel (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell an aggregate of [●] shares (the “Firm Shares”) of the Company’s ordinary shares with a nominal value of New Israeli Shekel (“NIS”) 0.01 per share (the “Ordinary Shares”), to the several underwriters (collectively, the “Underwriters”) named in Schedule I to this agreement (this “Agreement”), for whom BMO Capital Markets Corp. and RBC Capital Markets, LLC are acting as representatives (the “Representatives”). The Company has also agreed to grant to the Underwriters an option (the “Option”) to purchase up to an additional [●] ordinary shares of the Company (the “Option Shares”) on the terms set forth in Section 1(b) hereof. The Firm Shares and the Option Shares are hereinafter collectively referred to as the “Shares.”
2,200,000 Shares ANAPTYSBIO, INC. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENTUnderwriting Agreement • September 26th, 2018 • Anaptysbio Inc • Pharmaceutical preparations • New York
2,600,000 Shares SITO MOBILE, LTD. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • February 7th, 2018 • Sito Mobile, Ltd. • Services-business services, nec • New York
SITO Mobile, Ltd., a Delaware corporation (the “Company”), propose, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representative (the “Representative”), an aggregate of 2,600,000 shares (the “Firm Shares”) of the Company's common stock, $0.001 par value per share (the “Common Stock”). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 390,000 shares (the “Option Shares”) of Common Stock from the Company for the purpose of covering over-allotments in connection with the sale of the Firm Shares. The Firm Shares and the Option Shares are collectively referred to herein as the “Shares.”
•] Shares ANAPTYSBIO, INC. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENTUnderwriting Agreement • October 10th, 2017 • Anaptysbio Inc • Pharmaceutical preparations • New York
AnaptysBio, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell an aggregate of [•] shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), to the several underwriters (collectively, the “Underwriters”) named in Schedule I to this agreement (this “Agreement”), for whom Credit Suisse Securities (USA) LLC, Jefferies LLC and Stifel, Nicolaus & Company, Incorporated are acting as representatives (the “Representatives”). The Company has also agreed to grant to the Underwriters an option (the “Option”) to purchase up to an additional [•] shares of Common Stock (the “Option Shares”) on the terms set forth in Section 1(b) hereof. The Firm Shares and the Option Shares are hereinafter collectively referred to as the “Shares.”
4,000,000 Shares of Common Stock AMERICAN SUPERCONDUCTOR CORPORATION UNDERWRITING AGREEMENTUnderwriting Agreement • May 10th, 2017 • American Superconductor Corp /De/ • Motors & generators • New York
●] Shares ANAPTYSBIO, INC. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENTUnderwriting Agreement • January 17th, 2017 • Anaptysbio Inc • Pharmaceutical preparations • New York
1,150,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • December 1st, 2016 • Cadiz Inc • Water supply • California
SYSOREX GLOBAL HOLDINGS CORP. 5,250,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 25th, 2015 • Sysorex Global Holdings Corp. • Services-computer programming services • California
CONIFER HOLDINGS, INC. No Par Value Per Share UNDERWRITING AGREEMENTUnderwriting Agreement • July 30th, 2015 • Conifer Holdings, Inc. • Fire, marine & casualty insurance • New York
Conifer Holdings, Inc. a Michigan corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell an aggregate of [ ] shares (the “Firm Shares”) of the Company’s Common Stock, $[ ] par value per share (the “Common Stock”), to the several underwriters named in Schedule I (collectively, the “Underwriters”), for whom BMO Capital Markets Corp. (“BMOCM”) and Raymond James & Associates, Inc. (“Raymond James”) are acting as representatives (the “Representatives”). The Company has also agreed to grant to the Underwriters an option (the “Option”) to purchase up to an additional [ ] shares of Common Stock (the “Option Shares”) on the terms set forth in Section 1(b) hereof. The Firm Shares and the Option Shares are hereinafter collectively referred to as the “Shares.”
Benitec Biopharma Limited [•] American Depositary Shares Each Representing Twenty Ordinary Shares, no par value UNDERWRITING AGREEMENTUnderwriting Agreement • July 27th, 2015 • Benitec Biopharma LTD/ADR • Pharmaceutical preparations • New York
Benitec Biopharma Limited, ACN 068 943 662, an Australian corporation (the “Company”) that is listed on the Australian Securities Exchange (the “ASX”), proposes, subject to the terms and conditions stated herein, to issue and sell an aggregate of [•] ordinary shares of the Company, no par value (“Ordinary Shares”), to be delivered in the form of an aggregate of [•] American Depositary Shares (“ADS”), each ADS representing twenty (20) Ordinary Shares, to the several underwriters named in Schedule I (collectively, the “Underwriters”), for whom BMO Capital Markets Corp. (“BMOCM”) is acting as representative (the “Representative”). Such [•] ADSs are hereinafter called the “Firm ADSs”. The Company has also agreed to grant to the Underwriters an option (the “Option”) to purchase up to an additional [•] ADSs (the “Option ADSs” and, together with the Firm ADSs, the “Offered ADSs”) on the terms set forth in Section 1(b) hereof. The Ordinary Shares to be delivered in the form of the Firm ADSs ar
4,000,000 Shares of Common Stock AMERICAN SUPERCONDUCTOR CORPORATION UNDERWRITING AGREEMENTUnderwriting Agreement • April 28th, 2015 • American Superconductor Corp /De/ • Motors & generators • New York
WIDEPOINT CORPORATION 6,896,552 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 23rd, 2014 • Widepoint Corp • Services-computer integrated systems design • California
] Shares TOKAI PHARMACEUTICALS, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 2nd, 2014 • Tokai Pharmaceuticals Inc • Pharmaceutical preparations • New York
This press release is not an offer for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended.
Common Stock KINDRED BIOSCIENCES, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • April 3rd, 2014 • Kindred Biosciences, Inc. • Pharmaceutical preparations • New York
Common Stock KINDRED BIOSCIENCES, INC. FORM OF UNDERWRITING AGREEMENTUnderwriting Agreement • March 18th, 2014 • Kindred Biosciences, Inc. • Pharmaceutical preparations • New York
Kindred Biosciences, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [•] shares (the “Firm Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”). The Company also proposes to issue and sell to the several Underwriters up to an additional [•] shares (the “Additional Shares”) of Common Stock at the option of the Underwriters as provided in Section 2(c) below. The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares”. Leerink Partners LLC, BMO Capital Markets Corp. and Guggenheim Securities, LLC are acting as the representatives (the “Representatives”) of the several Underwriters in connection with the offering and sale of the Shares contemplated herein (the “Offering”). For purposes of this A
11,600,000 Shares GLOBAL EAGLE ENTERTAINMENT INC. Common Stock ($0.0001 Par Value) UNDERWRITING AGREEMENTUnderwriting Agreement • December 18th, 2013 • Global Eagle Entertainment Inc. • Communications services, nec • New York
Global Eagle Entertainment Inc., a Delaware corporation (the “Company”) proposes to sell to the several underwriters (the “Underwriters”) named on Schedule I hereto for whom you are acting as representative (the “Representative”) an aggregate of 11,600,000 shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value (the “Common Stock”). The respective amounts of the Firm Shares to be so purchased by the several Underwriters are set forth opposite their names on Schedule I hereto. The Company also proposes to sell at the Underwriters’ option an aggregate of up to 1,740,000 additional shares of the Company’s Common Stock (the “Option Shares”) as set forth below.
1,400,000 Shares TRI-COUNTY FINANCIAL CORPORATION Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 27th, 2013 • Tri County Financial Corp /Md/ • State commercial banks • New York
Tri-County Financial Corporation, a Maryland corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as the representative (the “Representative”) an aggregate of 1,400,000 shares (the “Firm Shares”) of the common stock, $0.01 par value per share, of the Company (“Common Stock”). The Company also proposes to sell to the several Underwriters, for the sole purpose of covering over-allotments in connection with the sale of the Firm Shares, at the option of the Underwriters, up to an additional 210,000 shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter referred to collectively as the “Shares.”
1,400,000 Shares TRI-COUNTY FINANCIAL CORPORATION Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 24th, 2013 • Tri County Financial Corp /Md/ • State commercial banks • New York
Tri-County Financial Corporation, a Maryland corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as the representative (the “Representative”) an aggregate of 1,400,000 shares (the “Firm Shares”) of the common stock, $0.01 par value per share, of the Company (“Common Stock”). The Company also proposes to sell to the several Underwriters, for the sole purpose of covering over-allotments in connection with the sale of the Firm Shares, at the option of the Underwriters, up to an additional 210,000 shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter referred to collectively as the “Shares.”
Chanticleer Holdings, Inc. 2,500,000 Units UNDERWRITING AGREEMENTUnderwriting Agreement • June 19th, 2012 • Chanticleer Holdings, Inc. • Services-management consulting services • Florida
Chanticleer Holdings, Inc, a Delaware corporation (the “Company”), proposes to sell to the several underwriters (the “Underwriters”) named in Schedule I hereto for whom you are acting as representatives each of Merriman Capital, Inc. and Dawson James Securities, Inc. collectively referred to herein as (the “Representative” “or “you”) an aggregate of 2,500,000 units (the “Firm Units”) at a price of [ ] per Unit, with each unit consisting of one share of the Company’s common stock, $0.0001 par value (the “Common Stock”), and one warrant (“Warrant”) to purchase one share of Common Stock. The respective amounts of Firm Units to be so purchased by each of the several Underwriters are set forth opposite their respective names in Schedule I hereto. The Company also proposes to sell, at the Underwriters’ option (“Over-allotment Option”), an aggregate of up to 375,000 additional units of the Company (the “Option Units”) as set forth below. The terms of the Warrants are provided for in the form
UNDERWRITING AGREEMENTUnderwriting Agreement • June 5th, 2012 • Monmouth Real Estate Investment Corp • Real estate investment trusts • New York
Monmouth Real Estate Investment Corporation, a Maryland corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell an aggregate of 2,000,000 shares (the “Firm Shares”) of the Company’s 7.875% Series B Cumulative Redeemable Preferred Stock, $0.01 par value per share, (the “Preferred Stock”) to the several underwriters named in Schedule I hereto (collectively, the “Underwriters”), for whom BMO Capital Markets Corp., a Delaware corporation (“BMOCM”), is acting as representative (the “Representative”). The Company has also agreed to grant to the Underwriters an option to purchase up to an additional 300,000 shares of Preferred Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter collectively referred to as the “Shares.”
Chanticleer Holdings, Inc. 2,500,000 Units UNDERWRITING AGREEMENTUnderwriting Agreement • June 5th, 2012 • Chanticleer Holdings, Inc. • Services-management consulting services • Florida
Chanticleer Holdings, Inc, a Delaware corporation (the “Company”), proposes to sell to the several underwriters (the “Underwriters”) named in Schedule I hereto for whom you are acting as representatives each of Merriman Capital, Inc. and Dawson James Securities, Inc. collectively referred to herein as (the “Representative” “or “you”) an aggregate of 2,500,000 units (the “Firm Units”) at a price of [ ] per Unit, with each unit consisting of one share of the Company’s common stock, $0.0001 par value (the “Common Stock”), and one warrant (“Warrant”) to purchase one share of Common Stock. The respective amounts of Firm Units to be so purchased by each of the several Underwriters are set forth opposite their respective names in Schedule I hereto. The Company also proposes to sell, at the Underwriters’ option (“Over-allotment Option”), an aggregate of up to 375,000 additional units of the Company (the “Option Units”) as set forth below. The terms of the Warrants are provided for in the form
UNDERWRITING AGREEMENTUnderwriting Agreement • May 29th, 2012 • Monmouth Real Estate Investment Corp • Real estate investment trusts • New York
Monmouth Real Estate Investment Corporation, a Maryland corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell an aggregate of [•] shares (the “Firm Shares”) of the Company’s [•]% Series B Cumulative Redeemable Preferred Stock, $0.01 par value per share, (the “Preferred Stock”) to the several underwriters named in Schedule I hereto (collectively, the “Underwriters”), for whom BMO Capital Markets Corp., a Delaware corporation (“BMOCM”), is acting as representative (the “Representative”). The Company has also agreed to grant to the Underwriters an option to purchase up to an additional [•] shares of Preferred Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter collectively referred to as the “Shares.”
Chanticleer Holdings, Inc. 5,000,000 Units UNDERWRITING AGREEMENTUnderwriting Agreement • May 21st, 2012 • Chanticleer Holdings, Inc. • Services-management consulting services • Florida
Chanticleer Holdings, Inc, a Delaware corporation (the “Company”), proposes to sell to the several underwriters (the “Underwriters”) named in Schedule I hereto for whom you are acting as representatives each of Merriman Capital, Inc. and Dawson James Securities, Inc. collectively referred to herein as (the “Representative” “or “you”) an aggregate of 5,000,000 units (the “Firm Units”) at a price of [ ] per Unit, with each unit consisting of one share of the Company’s common stock, $0.0001 par value (the “Common Stock”), and one warrant (“Warrant”) to purchase one share of Common Stock. The respective amounts of Firm Units to be so purchased by each of the several Underwriters are set forth opposite their respective names in Schedule I hereto. The Company also proposes to sell, at the Underwriters’ option (“Over-allotment Option”), an aggregate of up to 750,000 additional units of the Company (the “Option Units”) as set forth below. The terms of the Warrants are provided for in the form
4,500,000 Shares PROCERA NETWORKS, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • April 20th, 2012 • Procera Networks Inc • Services-computer programming services • New York
Procera Networks, Inc., a Nevada corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (collectively, the “Underwriters”) for whom you are acting as representative (the “Representative”), an aggregate of 4,500,000 shares (the “Firm Shares”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”). The Company also proposes to sell to the several Underwriters, for the sole purpose of covering over-allotments in connection with the sale of the Firm Shares, at the option of the Underwriters, up to an additional 675,000 shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter referred to collectively as the “Shares.”
•] SHARES TRUNKBOW INTERNATIONAL HOLDINGS LIMITED UNDERWRITING AGREEMENTUnderwriting Agreement • January 6th, 2011 • Trunkbow International Holdings LTD • Services-prepackaged software • New York
1,429,450 Shares of Common Stock CHINA AGRITECH, INC. UNDERWRITING AGREEMENT April 28, 2010Underwriting Agreement • April 29th, 2010 • China Agritech Inc • Agricultural chemicals • New York
China Agritech, Inc., a corporation organized and existing under the laws of Delaware (the “Company”) confirms its agreement, subject to the terms and conditions set forth herein, with each of the underwriters listed on Exhibit A hereto (collectively, the “Underwriters”), for whom Rodman & Renshaw, LLC (“Rodman”) is acting as representative (in such capacity, the “Representative”), to sell and issue to the Underwriters an aggregate of 1,243,000 shares of common stock (the “Firm Shares”) par value $0.001 per share (the “Common Stock”).
8,500,000 Shares DELCATH SYSTEMS, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • November 18th, 2009 • Delcath Systems Inc • Surgical & medical instruments & apparatus • New York
MGIC INVESTMENT CORPORATION Common Stock UNDERWRITING AGREEMENT dated •, 2008 Banc of America Securities LLCUnderwriting Agreement • March 18th, 2008 • Mgic Investment Corp • Surety insurance • New York
MGIC INVESTMENT CORPORATION, a Wisconsin corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of • shares (the “Firm Shares”) of its common stock, par value $1.00 per share (the “Common Stock”). In addition, the Company has granted to the Underwriters an option to purchase up to an additional • shares (the “Optional Shares”) of Common Stock, as provided in Section 2. The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Shares”. Banc of America Securities LLC has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Shares.
